The present investigation elucidates the deleterious effects of three prototypical antihypertensive drugs namely, propranolol, clonidine and captopril on the erectile physiology. In order to delineate the direct drug effects from vascular insuf®ciency inherent in hypertensive states, the study was conducted on a normotensive animal model. The adverse effects of these drugs were estimated as changes in sexual behaviour and intracavernous pressure response to electrical stimulation in the treated rats compared to normal age-matched controls (n 10, each group). Copulation studies indicated signi®cant impairment of sexual function in the groups on propranolol and clonidine. The cavernous pressure response to nerve stimulation at the end of sixteen weeks further reinforced the gross compromise on sexual function in these two treated groups. In contrast, the captopril administration produced only marginal alterations to the responses recorded. The results from this study clearly indicate that propranolol and clonidine interfere with sexual behaviour and nerve mediated response to erection whereas captopril which is devoid of signi®cant effects on these parameters, may be a better therapeutic option.
Introduction
Many clinical studies have reported erectile dysfunction secondary to antihypertensive drug intake, with alarming regularity. Although most of these clinical observations have not been tested, they may have become accepted as factual and cause for noncompliance. 1 In view of the high prevalence of hypertension world-wide, the effect of therapeutic measures on sexual function needs to be explored and categorised, especially when a direct correlation is not readily apparent. 2 Reports of impotence encompass almost all clinically important groups of antihypertensives. 3 Nevertheless, with disparate mechanisms of action, the scienti®c evidence to substantiate this iatrogenic effect is often limited. 4 It is sometimes believed that the erectile dysfunction secondary to these agents is due to diminution of pressure head below the critical level for adequate penile perfusion. 5 In the presence of an additional arterial risk factor namely, hypercholesterolaemia, hypertension per se 6, 7 and antihypertensive drug intake 8 are known to promote atherogenesis and secondary sexual dysfunction. Furthermore, there is no discernible morphological difference between long-standing hypertension and atherosclerosis. In this connection, the cofactorial role of endothelial dysfunction and decreased nitric oxide synthesis has been evaluated 9 and of considerable clinical relevance is the erectile dysfunction reported in untreated hypertensive men. 10, 11 In such a situation, the problem gets further compounded by a prescribed antihypertensive, if impotence is one of its known adverse effects. 12 While there is no denying the risk of isolated erectile dysfunction in untreated cases, 4 it is often not recognised whether the impairment in controlled hypertension is due to the in¯uence of disease, drugs or both. Therefore, the mechanisms of antihypertensive induced erectile dysfunction are far from being clari®ed due to the complex interplay of underlying vascular insuf®ciency in a clinical setting. 13, 14 The issue becomes all the more persuasive when consideration is given to the need of protecting patients from an exaggerated adverse effect while being conscious of not withholding treatment that may otherwise have its greatest bene®t.
However, at least some of the concerns and perplexities in this area have been overridden by prospective epidemiological data which have shown that with many antihypertensives, impotence is a dose-related phenomenon. A review of studies with beta adrenoceptor blockers has indicated an erectile dysfunction and impaired libido when the total daily dose of propranolol exceeded 120 mg. 15 Furthermore, these symptoms are superimposed on its other doserelated side effects namely bradycardia, hypotension and bronchospasm. 16 Evidence also attributes the sexual side effects to interactions with central tryptaminergic receptors and peripheral reduction in serum testosterone levels. 17, 18 Other antihypertensive agents such as methyldopa, clonidine, monoamine oxidase inhibitors and guanethidine have also been implicated in varying degrees of erectile dysfunction. Many of these drugs act centrally rather than on the corporal vasculature or smooth muscle. A study by Melman and associates attributes this side effect of methyldopa in rats to central mechanisms. 19 Clonidine lowers blood pressure through its effects on a 2 adrenergic receptors in the central nervous system. There is a 17±30% incidence of impotence reported in patients treated with clonidine; this is associated with retrograde ejaculation. 20, 21 In case of alpha blockers, a possible explanation for the development of impotence is accompanying ejaculatory incompetence.
Antihypertensive drugs generally thought not to cause sexual dysfunction include angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers. 23, 23 In a hypertensive on medication, the drug effects are widely spread and erectile dysfunction is the result of an interaction on different homeostatic mechanisms, altered by the disease state. Hence, only a prolonged drug intake in normotensives will elucidate the sexual adverse effects of these agents without the in¯uence of secondary changes of hypertension. Active research studying the clinical corollaries in animal models can ameliorate the rampant non-compliance to these drugs. Unfortunately, there is a paucity of experimental studies using rigid controls to authenticate these intriguing general relationships. The present investigation was therefore designed to determine possible alterations in erectile function to some of the antihypertensives through systematic studies on sexual behaviour and responses to cavernous nerve stimulation in a suitable normotensive animal model. In view of the close resemblance to sexual behaviour in humans, 24 the rat model established in this study may help to ®ll some of the gaps in our knowledge of drug-induced dysfunction.
Methods
Forty sexually mature male Sprague Dawley (SD) rats in the weight range of 250±300 g were randomly assigned to four experimental groups, each comprising ten animals. All were housed under reverse 12 h light cycle and controlled room temperature (21 C) with standard rat chow and water accessed ad libitum.
Drug administration
The speci®c antihypertensive drug at advocated dosage schedule 25 was administered to animals of test groups by gavage daily for 16 weeks. Group I received 1.25 mg of propranolol (Sigma Chemical Co.) in two divided doses, Group II; 2.5 mg of clonidine (Boehringer Ingelheim) as a single dose and Group III ingested 2.5 mg of captopril (Pharmaforte) in two divided doses.
Copulation studies
At the initiation of the experiment, all the forty animals participating in the study were sexually assessed with proceptive females to get the baseline activity for each group. Oestrous behaviour was induced in the ovariectomised 26 animals through sequential, subcutaneous administration of 30 mg of oestradiol benzoate (Sigma Chemical Co.) and 1.5 mg of progesterone (Biologici Italia Labs.), 48 h and 4 h prior to the study respectively. Copulation tests were carried out between 14.00 and 19.00 h in a separate room under dim red illumination with the male rat in a rectangular perspex arena (42 6 38 6 20 cm). Following a 10 min adaptation period, the receptive female was introduced and the copulatory behaviour 27 recorded as individual events of mounts and intromissions which culminated in ejaculation (Photographs 1± 4). The parameters given due consideration included mount, intromission and ejaculation latencies (ML, IL & EL), the number of mounts and intromissions (MF & IF) and post-ejaculatory interval (PEI). Activities such as anogenital investigation and pelvic grooming were also assessed. After recording the baseline function, these tests were repeated at 6, 12 and 16 weeks for animals of all the experimental groups.
Cavernous pressure evaluation
At the end of 16 weeks, the male SD rate (500±750 g) were anaesthetised with pentobarbital sodium (45 mgakg I.P with 10 mgakg I.V supplement, when necessary). The left external jugular vein and the right carotid artery were cannulated (PE 50 tubing) respectively, for drug administration and blood pressure (BP) monitoring. The trachea was Sexual dysfunction related to antihypertensive agents B Srilatha et al cannulated for ventilation. Through a lower median incision, the lateral prostate was exposed and the cavernous nerve carefully isolated and suspended by platinum wire electrodes (with 1 mm interelectrode distance) for stimulation. 28 A 27 gauge needle ®lled with heparinized saline (250 i.u.aml) was placed in the penile crus (PE 10 tubing) for recording the intracavernous pressure (ICP) response to nerve stimulation. The pressure recordings were obtained at the optimal voltage and frequency of 2 v and 20 hz over 1 ms duration. The contact time was 30±45 s stimulation. The mean blood and intracavernous pressure changes were measured with pressure transducers (Ugo Basile) and recorded with the MacLab analogue-digital converter (AD instruments).
Statistical analysis
Data are expressed as mean AE s.e.m. Analysis of variance (ANOVA) and non-parametric test for Kindependent samples were used to compare the results from different experimental groups with normal controls. A value of P`0X05 was considered statistically signi®cant.
Results

Copulation studies
The untreated male rats vigorously pursued the females, investigated them anogenitally and made abortive mounting attempts more frequently before intromission and ejaculation.
In comparison, the sexual refractoriness in the propranolol-treated group became apparent at 12 Sexual dysfunction related to antihypertensive agents B Srilatha et al weeks and was marked at 16 weeks of the study. Dif®culty in gaining intromission was perceived as longer latencies (5.35 AE 0.91 min) and inter-intromission intervals. This group was also characterised by the greatest amount of time spent in approaching the female (the preintromission mount duration being 3.13 AE 0.57 min) and a tendency to move away from the female before genital grooming between two consecutive mountsaintromissions. At 16 weeks, only two out of the ten treated animals successfully ejaculated and completed the copulatory pattern. The rats on clonidine also showed gross deterioration in the events leading to ejaculation with just two animals completing the pattern at 16 weeks. The mount and intromission latencies for this group were 2.62 AE 0.62 min and 4.49 AE 0.77 min respectively. In marked contradistinction, the captopril treated rats gained intromission sooner (IL: 1.17 AE 0.29 min), spent less time between mounts and intromissions and ejaculated at 15.12 AE 0.75 min. Despite continued medication, as many as nine of the ten rats completed the entire pattern successfully at 16 weeks (Table 1, Figure 1± 3).
Cavernous pressure evaluation
In the untreated rats, stimulation of cavernous nerve induced a rapid intracavernous pressure change (mean increase from the baseline: 54.62 AE 0.67 mmHg) associated with tumescence. At the standard stimulation criteria, the BPaICP ratio for this group was 1.35 AE 0.07 (Table 2) .
Propranolol and clonidine pre-treatment caused reductions in systemic arterial pressure and signi®-cant impairment of the mean ICP elevation to nerve stimulation. The BPaICP ratios for the two groups were 2.4 AE 0.34 and 2.03 AE 0.27 respectively. The functional impairment on captopril treatment was Figure 1 Mount and intromission latencies. The latencies recorded in the different groups of rats (n 10). The statistical difference by one way ANOVA and non-parametric test for K independent samples is ÃP`0X05. Copulatory pattern in three groups of drug treated and control rats (Groups I±IV) at sixteen weeks. The statistical signi®cance by one way ANOVA and the non-parametric test for K-independent samples is *P<0X05 Figure 2 Mount and intromission frequencies. The frequencies recorded in the different groups of rats (n 10). The statistical difference by one way ANOVA and non-parametric test for K independent samples is ÃP`0X05.
Sexual dysfunction related to antihypertensive agents B Srilatha et al much less pronounced despite signi®cantly low mean systemic blood pressure of 64.22 AE 2.43 mmHg (Figure 4) . The BPaICP ratio of 1.44 AE 0.15 compared well with that for the control rats.
Discussion
This present study provides the ®rst supportive evidence for drug induced erectile dysfunction through major insights into its pathophysiology in normotensive animals. Since rat as an experimental animal, is identical with many behavioural and endocrine aspects of sexual activity in man, 24, 29 the predilection secondary to these drugs may be directly extrapolated to the human experience. Furthermore, the intracavernous pressure response in rats to nerve stimulation yields a suitable index for the quantitative assessment of penile erection. With the resting ICP and the subsequent increment at maximal erection paralleling those in man, 30 the rat provides an appropriate model for evaluation of drug induced changes in the central integrative mechanism of penile erection. With the parameters of nerve stimulation constant, the pressure response obtained in the treated animals provides an objective measurement of the ICP changes secondary to drugs.
In keeping with the clinical reports on noncompliance to propranolol, 31±33 this investigation demonstrates a gross compromise on sexual drive in the rats treated for sixteen weeks. The drug induced increases in sexual latencies and decrements in the frequencies are in line with statistically signi®cant alterations in ICP and the BPaICP ratio. While propranolol is a widely prescribed therapeutic agent in patients under 50 y of age, its sexual side effects are reported to be central, 12 sequel to its af®nity for the serotonin receptor subtype 5HT 1A and blockade of the adenylate cyclase mediated facilitatory pathway for erectile responses. 17 It is known that the contractile alpha 1 adrenoceptor activity in the cavernosum is markedly potentiated in the presence of propranolol. 34 Furthermore, there is clinical and experimental evidence for reduction of total and free testosterone levels on continued medication with propranolol 18, 35 which is likely to impede the NO mediated erectile activity. 36 Therefore these various cellular alterations may explain the direct propranolol-induced side effect in this investigation and the reduction in subjective and physiological measures of sexual function in patients on treatment. Sexual dysfunction related to antihypertensive agents B Srilatha et al
In our study, the effects of clonidine pre-treatment paralleled those due to propranolol, albeit less pronounced. Taken together with the clinical propensity, 37±40 the signi®cant changes in ICP and BPaICP ratio indicate a direct iatrogenic suppression of sexual activity on prolonged intake. Clonidine, the central sympathetic out¯ow inhibitor, acts by stimulating the postsynaptic a2 adrenoceptors in the pontomedullary region and the sexual side effect pro®le is inseparable from its hypotensive action. 40, 41 Facilitation of neuropeptide Y mediated activity and a delay in bulbocavernous re¯ex may also contribute to its negative sexual side effects. 42 Other noted effects include increased production of oestradiol and activation of aromatase. 43 Furthermore, the cavernosal vasoconstriction mediated through peripheral a 2 adrenoceptors may aggravate the erectile failure. 44 More recently, the effect of clonidine on the I 1 imidazoline receptors at the nucleus reticularis lateralis is identi®ed as the cause for hypotension. Since a selective stimulation of these receptors with analogs is devoid of the undesirable sexual side effects encountered with clonidine, the newer I 1 imidazoline receptor agonists such as moxonidine and rilmenidine 39,40 may be better therapeutic options for hypertension.
This present data suggests that captopril, the dipeptidyl carboxypeptidase inhibitor and a ®rst line agent for antihypertensive therapy in the elderly, is well tolerated with evidence for negligible alteration in sexual behaviour on continued medication. The results from pressure recording in this group of rats also indicate that captopril is a more potent hypotensive than the other two agents, at the chosen dosage regimen. In spite of the statistically signi®cant reduction in blood and cavernous pressures, the BPaICP ratio for this group parallels that obtained in age matched controls. Our data bear experimental evidence for the lower incidence of erectile dysfunction reported in patients. 45±48 Captopril is shown to mediate the release of PGE 2 and substance P in the genitals with potential bene®ts of vasodilation and sexual arousal. 42 , 49 Croog and associates have shown that the reduced epinephrine re¯ex can be further ef®ca-cious in correcting psychogenic impotence. 50 
Conclusion
As stated earlier, 5 the gross reduction in systemic blood pressure may be expected to interfere with penile tumescence and rigidity through decreased perfusion pressure of the cavernosal sinuses. However, in contradistinction to this view, the results from the behavioural studies of this present investigation authenticate the sexual safety of captopril amidst its signi®cant hypotensive effect. Another important outcome of this investigation is the observation that ICP changes are not linearly proportional to reduction in systemic blood pressure. Since ICP is an objective measurement, this model should be given due consideration while screening drugs for erectile dysfunction. In summary, it is evident from the components of this study that the ACE inhibitors are better tolerated than the conventional sympatholytics and should be the drugs of choice when indicated.
